ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AstraZeneca Tunes Drug Portfolio

by Jean-François Tremblay
August 3, 2015 | APPEARED IN VOLUME 93, ISSUE 31

AstraZeneca and Fujifilm Kyowa Kirin Biologics (FKB) are forming a 50-50 joint venture to develop a biosimilar of Avastin, a Genentech cancer drug. The new venture will pay $45 million to FKB for a biologic that is undergoing Phase I clinical trials in Europe. FKB is a biosimilars joint venture set up in 2012 by Fujifilm and Kyowa Hakko Kirin. Separately, AstraZeneca will get up to $300 million for selling Genzyme the rights to Caprelsa, a drug for treating aggressive and symptomatic medullary thyroid carcinoma, a rare disease. Caprelsa registered sales of $48 million in 2014.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment